» Articles » PMID: 39994734

Hippocampal Mitophagy Alterations in MAPT-associated Frontotemporal Dementia with Parkinsonism

Overview
Publisher Biomed Central
Specialty Neurology
Date 2025 Feb 25
PMID 39994734
Authors
Affiliations
Soon will be listed here.
Abstract

The enzyme pair PINK1 and PRKN together orchestrates a cytoprotective mitophagy pathway that selectively tags damaged mitochondria with phospho-serine 65 ubiquitin (pS65-Ub) and directs them for autophagic-lysosomal degradation (mitophagy). We previously demonstrated a significant accumulation of pS65-Ub signals in autopsy brains of sporadic Lewy body disease and Alzheimer's disease cases, which strongly correlated with early tau pathology. In this study, we extended our analysis to a series of pathologically confirmed cases of frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) harboring different pathogenic mutations in MAPT, the gene encoding tau. We assessed the morphology, levels, and distribution of the mitophagy tag pS65-Ub in several affected brain regions and hippocampal subregions of these cases. While tau pathological burden was similarly increased across all FTDP-17 cases, pS65-Ub immunopositive signals were strongly accumulated in P301L cases and only weakly present in N279K cases. In the hippocampus of both mutation groups, the density of pS65-Ub positive cells was overall the greatest in the dentate gyrus followed by the subiculum, CA1, and CA2/3, with the CA4 showing only minimal presence. Notably, positive cells in the subiculum carried greater numbers and particularly vacuolar pS65-Ub structures, while cells in the dentate gyrus mostly contained fewer and rather granular pS65-Ub inclusions. Single cell analyses revealed differential co-localization of pS65-Ub with mitochondria, autophagosomes, and lysosomes in these two regions. Together, our study demonstrates distinct mitophagy alteration in different FTDP-17 MAPT cases and hint at selective organelle failure in the hippocampal subregions that was associated with the P301L mutation.

References
1.
Haussmann R, Wysocki M, Brandt M, Hermann A, Donix M . MAPT mutation associated with frontotemporal dementia and parkinsonism (FTDP-17). Int Psychogeriatr. 2016; 29(5):869-871. DOI: 10.1017/S1041610216002192. View

2.
Gibson G, Shi Q . A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. J Alzheimers Dis. 2010; 20 Suppl 2:S591-607. PMC: 3085842. DOI: 10.3233/JAD-2010-100336. View

3.
Weitzman S, Narasimhan S, He Z, Changolkar L, McBride J, Zhang B . Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo. J Neuropathol Exp Neurol. 2020; 79(9):941-949. PMC: 7445034. DOI: 10.1093/jnen/nlaa086. View

4.
Cabezas-Opazo F, Vergara-Pulgar K, Perez M, Jara C, Osorio-Fuentealba C, Quintanilla R . Mitochondrial Dysfunction Contributes to the Pathogenesis of Alzheimer's Disease. Oxid Med Cell Longev. 2015; 2015:509654. PMC: 4499633. DOI: 10.1155/2015/509654. View

5.
Dawson T, Dawson V . Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. Annu Rev Pharmacol Toxicol. 2017; 57:437-454. PMC: 11323062. DOI: 10.1146/annurev-pharmtox-010716-105001. View